HRP20192006T1 - Antitijela specifična za fcrn - Google Patents

Antitijela specifična za fcrn Download PDF

Info

Publication number
HRP20192006T1
HRP20192006T1 HRP20192006TT HRP20192006T HRP20192006T1 HR P20192006 T1 HRP20192006 T1 HR P20192006T1 HR P20192006T T HRP20192006T T HR P20192006TT HR P20192006 T HRP20192006 T HR P20192006T HR P20192006 T1 HRP20192006 T1 HR P20192006T1
Authority
HR
Croatia
Prior art keywords
seq
antibody
fcrn
binding fragment
fragment
Prior art date
Application number
HRP20192006TT
Other languages
English (en)
Inventor
Paul Alan ATHERFOLD
Thomas Allen Ceska
Helene Margaret Finney
Lara KEVORKIAN
Kaushik Sarkar
Bryan John Smith
Kerry Louise Tyson
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49818582&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20192006(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of HRP20192006T1 publication Critical patent/HRP20192006T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)

Claims (22)

1. Anti-FcRn antitijelo ili njegov vezujući fragment koji se sastoji od (i) teškog lanca ili fragmenta teškog lanca koji sadrži varijabilnu regiju koja se sastoji od sekvence navedene u SEQ ID NO:25 i (ii) lakog lanca ili fragmenta lakog lanca koji sadrži varijabilnu regiju koja se sastoji od sekvence navedene u SEQ ID NO: 16.
2. Anti-FcRn antitijelo ili njegov vezujući fragment prema patentnom zahtjevu 1, naznačen time, što, je antitijelo ili vezujući fragment scFv, Fv, Fab ili Fab' fragment.
3. Fab' fragment anti-FcRn antitijela prema patentnom zahtjevu 2 koji sadrži teški lanac koji se sastoji od sekvence navedene u SEQ ID NO: 33 i laki lanac koji se sastoji od sekvence navedene u SEQ ID NO: 20.
4. Fab fragment anti-FcRn antitijela prema patentnom zahtjevu 2 koji sadrži teški lanac koji se sastoji od sekvence navedene u SEQ ID NO: 29 i laki lanac koji se sastoji od sekvence navedene u SEQ ID NO: 20.
5. Anti-FcRn antitijelo ili njegov vezujući fragment prema bilo kojem patentnom zahtjevu od 1 do 4, naznačen time, što je antitijelo ili vezujući fragment konjugiran na polimer, primjerice odabran iz škroba, albumina i polietilenglikola.
6. Anti-FcRn antitijelo ili njegov fragment prema patentnom zahtjevu 5, naznačen time, što je polimer PEG, primjerice s molekularnom masom u rasponu od 5 do 50 kDa.
7. Anti-FcRn antitijelo prema patentnom zahtjevu 1, naznačeno time, što je antitijelo antitijelo pune dužine.
8. Anti-FcRn antitijelo prema patentnom zahtjevu 7, naznačeno time, što je antitijelo pune dužine odabrano iz skupine koja se sastoji od IgG1, IgG4 i IgG4 S241P.
9. Anti-FcRn antitijelo prema patentnom zahtjevu 1, patentnom zahtjevu 7 ili patentnom zahtjevu 8 koje sadrži teški lanac koji se sastoji od sekvence navedene u SEQ ID NO: 37, SEQ ID NO:39 ili SEQ ID NO:73 i laki lanac koji se sastoji od sekvence navedene u SEQ ID NO: 20.
10. Anti-FcRn antitijelo ili njegov fragment prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time, što je antitijelo ili njegov vezujući fragment Fab-dsFv koji sadrži teški lanac koji se sastoji od sekvence navedene u SEQ ID NO: 42 i laki lanac koji se sastoji od sekvence navedene u SEQ ID NO: 40.
11. Anti-FcRn antitijelo ili njegov vezujući fragment prema bilo kojem patentnom zahtjevu od 1 do 10, koji blokira vezivanje ljudskog IgG-a za ljudski FcRn.
12. Anti-FcRn antitijelo ili njegov vezujući fragment prema bilo kojem patentnom zahtjevu od 1 do 11 koji se ne vezuje za ljudski β2 mikroglobulin (SEQ ID NO:72).
13. Izolirana sekvenca DNK koja šifrira teški/e i laki/e lanac/lance antitijela prema bilo kojem patentnom zahtjevu od 1 do 12.
14. Klonirajući ili ekspresijski vektor koji se sastoji od jedne ili više sekvenci DNK prema patentnom zahtjevu 13.
15. Vektor prema patentnom zahtjevu 14, naznačen time, što se vektor sastoji od (i) sekvence navedene u SEQ ID NO: 30, 32, 34 ili 36 i sekvence navedene u SEQ ID NO: 21 ili 24 ili (ii) sekvence navedene u SEQ ID NO: 38 i sekvence navedene u SEQ ID NO: 22 ili (iii) sekvence navedene u SEQ ID NO: 74 i sekvence navedene u SEQ ID NO: 22 ili (iv) sekvence navedene u SEQ ID NO: 41 i sekvence navedene u SEQ ID NO: 43.
16. Domaćinska stanica koja se sastoji od jednog ili više klonirajućih ili ekspresijskih vektora prema patentnom zahtjevu 14 ili patentnom zahtjevu 15.
17. Proces za proizvodnju antitijela koje se specifično vezuje za ljudski FcRn, koji se sastoji od uzgajanja domaćinske stanice prema patentnom zahtjevu 16 i izoliranja antitijela.
18. Farmaceutski pripravak koji sadrži anti-FcRn antitijelo ili njegov vezujući fragment kako je definirano u bilo kojem patentnom zahtjevu od 1 do 12 u kombinaciji s jednim ili više farmaceutski prihvatljivih ekscipijensa, razrjeđivača ili nosača.
19. Farmaceutski pripravak prema patentnom zahtjevu 18 koji sadrži druge djelatne tvari.
20. Antitijelo ili njegov vezujući fragment kako je definirano u bilo kojem patentnom zahtjevu od 1 do 12 ili pripravak kako je definirano u patentnom zahtjevu 18 ili 19 za primjenu u terapiji.
21. Antitijelo ili njegov vezujući fragment kako je definirano u bilo kojem patentnom zahtjevu od 1 do 12 ili pripravak kako je definirano u patentnom zahtjevu 18 ili 19, za primjenu u liječenju autoimune bolesti, kao što je miastenija gravis, obični pemfigus, optički neuromijelitis, Guillan-Barreov sindrom, lupus, idiopatska trombocitopenična purpura i trombotična trombocitopenična purpura.
22. Antitijelo ili njegov vezujući fragment kako je definirano u bilo kojem patentnom zahtjevu od 1 do 12 ili pripravak kako je definirano u patentnom zahtjevu 18 ili 19, za primjenu u liječenju kronične upalne demijelinacijske polineuropatije (CIDP), paraproteinemičke polineuropatije, refraktorne epilepsije, hemolitičke anemije, Goodpastureovog sindroma, nekompatibilnosti krvnih grupa ABO, lupusnog nefritisa, bubrežnog vaskulitisa, sklerodermije, fibroznog alveolitisa, dilatirane kardiomiopatije, Graveove bolesti, dijabetesa tipa 1, autoimunog dijabetesa, pemfigusa, ANCA-pozitivnog vaskulitisa, dermatomiozitisa, Sjorgenove bolesti i reumatoidnog artritisa.
HRP20192006TT 2013-11-13 2019-11-06 Antitijela specifična za fcrn HRP20192006T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1320066.2A GB201320066D0 (en) 2013-11-13 2013-11-13 Biological products
EP14800000.3A EP3068800B1 (en) 2013-11-13 2014-11-12 Antibodies specific to fcrn
PCT/EP2014/074409 WO2015071330A1 (en) 2013-11-13 2014-11-12 Antibodies specific to fcrn

Publications (1)

Publication Number Publication Date
HRP20192006T1 true HRP20192006T1 (hr) 2020-02-07

Family

ID=49818582

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192006TT HRP20192006T1 (hr) 2013-11-13 2019-11-06 Antitijela specifična za fcrn

Country Status (31)

Country Link
US (3) US10273302B2 (hr)
EP (2) EP3068800B1 (hr)
JP (2) JP6584398B2 (hr)
KR (1) KR102366114B1 (hr)
CN (1) CN105814080B (hr)
AR (1) AR098408A1 (hr)
AU (1) AU2014350257B2 (hr)
BR (1) BR112016010822A2 (hr)
CA (1) CA2928341A1 (hr)
CL (2) CL2016001147A1 (hr)
CY (1) CY1122214T1 (hr)
DK (1) DK3068800T3 (hr)
EA (1) EA035142B1 (hr)
ES (1) ES2748570T3 (hr)
GB (1) GB201320066D0 (hr)
HR (1) HRP20192006T1 (hr)
HU (1) HUE046511T2 (hr)
IL (1) IL245265B (hr)
LT (1) LT3068800T (hr)
MA (1) MA39096B1 (hr)
MX (1) MX2016005956A (hr)
PE (1) PE20160662A1 (hr)
PH (1) PH12016500753A1 (hr)
PL (1) PL3068800T3 (hr)
PT (1) PT3068800T (hr)
SG (1) SG11201603307XA (hr)
SI (1) SI3068800T1 (hr)
TN (1) TN2016000173A1 (hr)
TW (1) TWI651330B (hr)
UY (1) UY35835A (hr)
WO (1) WO2015071330A1 (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
MX2016008782A (es) 2014-01-15 2016-09-08 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
AU2017257680A1 (en) 2016-04-25 2018-12-06 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
SG11202103801UA (en) 2018-10-16 2021-05-28 UCB Biopharma SRL Method for the treatment of myasthenia gravis
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1638A (en) 1872-08-31 J.M. Taylor Improvement on railway snow-plows
DE2063975C3 (de) 1970-12-28 1973-09-27 Deutsche Vergaser Gmbh & Co Kg, 4040 Neuss Brennstoffzumeßduse mit temperatur abhangig veränderbarem Austrittsquer schnitt fur Vergaser insbesondere Gleich druckvergaser, fur Brennkraftmaschinen
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
CA2431600C (en) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
JP2006517167A (ja) * 2002-10-04 2006-07-20 ランサー・パートナーシップ・リミテッド 多銘柄の冷飲料ディスペンサ
CA2507004A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
JP2007501847A (ja) * 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0506912D0 (en) * 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
US20100266530A1 (en) 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
EP1928506A4 (en) 2005-08-19 2009-10-21 Abbott Lab IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
EP1986690A4 (en) 2006-01-25 2009-05-13 Univ New York State Res Found ANTIBODIES AGAINST FCRN FOR THE TREATMENT OF AUTO / ALLO IMMUNOIDES
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US8906844B2 (en) 2007-08-09 2014-12-09 Biogen Idec Hemophilia Inc. Immunomodulatory peptides
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
SG196839A1 (en) 2008-04-25 2014-02-13 Dyax Corp Antibodies against fcrn and use thereof
US20100048488A1 (en) 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
ES2748583T3 (es) 2011-06-02 2020-03-17 Dyax Corp Proteínas de unión al receptor Fc
MX351502B (es) 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
KR20130071961A (ko) * 2011-12-21 2013-07-01 한올바이오파마주식회사 ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products

Also Published As

Publication number Publication date
DK3068800T3 (da) 2019-10-21
PL3068800T3 (pl) 2020-02-28
AU2014350257A1 (en) 2016-05-26
EP3572433A1 (en) 2019-11-27
TWI651330B (zh) 2019-02-21
MA39096B1 (fr) 2019-12-31
KR102366114B1 (ko) 2022-02-21
HUE046511T2 (hu) 2020-02-28
US20160264668A1 (en) 2016-09-15
MX2016005956A (es) 2016-08-17
ES2748570T3 (es) 2020-03-17
EP3068800A1 (en) 2016-09-21
TN2016000173A1 (en) 2017-10-06
CN105814080B (zh) 2019-09-24
IL245265B (en) 2020-08-31
US20220162311A1 (en) 2022-05-26
BR112016010822A2 (pt) 2017-12-05
CL2019001671A1 (es) 2019-10-11
PH12016500753B1 (en) 2016-05-30
PH12016500753A1 (en) 2016-05-30
TW201525002A (zh) 2015-07-01
AU2014350257B2 (en) 2020-04-02
US20190270811A1 (en) 2019-09-05
IL245265A0 (en) 2016-06-30
PT3068800T (pt) 2019-10-29
US10273302B2 (en) 2019-04-30
EA201690992A1 (ru) 2016-10-31
CA2928341A1 (en) 2015-05-21
WO2015071330A1 (en) 2015-05-21
EP3068800B1 (en) 2019-08-07
CY1122214T1 (el) 2020-11-25
GB201320066D0 (en) 2013-12-25
AR098408A1 (es) 2016-05-26
SI3068800T1 (sl) 2019-11-29
CN105814080A (zh) 2016-07-27
UY35835A (es) 2015-06-30
JP6584398B2 (ja) 2019-10-02
KR20160077211A (ko) 2016-07-01
JP2020018301A (ja) 2020-02-06
PE20160662A1 (es) 2016-07-09
LT3068800T (lt) 2019-11-11
JP2016537976A (ja) 2016-12-08
SG11201603307XA (en) 2016-05-30
US11220547B2 (en) 2022-01-11
CL2016001147A1 (es) 2017-02-17
EA035142B1 (ru) 2020-05-06

Similar Documents

Publication Publication Date Title
HRP20191334T1 (hr) Anti-fcrn antitijela
HRP20192006T1 (hr) Antitijela specifična za fcrn
HRP20201191T1 (hr) Mutirani multispecifični fab fragmenti antitijela
HRP20200174T1 (hr) Antitijela antigena 2 anti-krvne dendritične stanice i njihova uporaba
HRP20191697T1 (hr) Vezujuće molekule za bcma i cd3
HRP20231579T1 (hr) Anti-ctla-4 antitijela i postupci njihove upotrebe
CA2953714C (en) Anti-tnfa antibodies with ph-dependent antigen binding
RU2016146486A (ru) Гуманизированные антитела против cd269 (bcma)
SI2195023T1 (en) Humanized anti-CXCR5 antibodies, their derivatives and their uses
HRP20201377T1 (hr) Vezujuće molekule specifične za il-21 i njihova upotreba
JP2018121657A5 (hr)
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
RU2016100892A (ru) Антитела против tweakr и их применение
IL245001B (en) Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses
FI3137504T3 (fi) Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
JP2016514463A5 (hr)
NZ711451A (en) Anti-c5 antibodies having improved pharmacokinetics
RU2016132757A (ru) Антитела, направленные против интерлейкина-33 (il-33)
SI2699601T1 (en) PROTITOLIC POLYPETIDES AS THE CD40 ANTAGONISTS
JP2013538057A5 (hr)
RU2017128882A (ru) Антитела к биотину и способы их применения
JP2017504578A5 (hr)
JP2012143232A5 (hr)
JP2012514997A5 (hr)
CA2818635C (en) Antibodies selective for cells presenting erbb2 at high density